Executive Briefings

Extending Channel Vision Today: Unlocking the Value in the 867 Product Transfer and Resale Report

For pharmaceutical manufacturers, the EDI 867 Product Transfer and Resale Report provides invoice-level details on all product movements between wholesalers and their downstream customers. While manufacturers have gained significant insight into channel activities through the EDI 852 report, the EDI 867 largely remains underutilized due to the prodigious volumes of data and the challenges of reconciling it with other data sources. Yet, buried in the details of the 867 transaction stream are precise images of the activities of downstream channel customers, which can reveal discrepancies that can compromise manufacturer revenue, product availability and integrity, and even patient safety. For these reasons, mastering the 867 can yield significant rewards.

This paper demystifies the often incomplete and always massive EDI 867 document to assess its true economic value to the pharmaceutical manufacturer and, by extension, to wholesaler partners. As the distribution channel becomes more collaborative, capturing the essentials of the 867 provides another step towards a transparent and safe route to the patient.

Complete white paper can be found at: http://www.edgedynamics.com/

For pharmaceutical manufacturers, the EDI 867 Product Transfer and Resale Report provides invoice-level details on all product movements between wholesalers and their downstream customers. While manufacturers have gained significant insight into channel activities through the EDI 852 report, the EDI 867 largely remains underutilized due to the prodigious volumes of data and the challenges of reconciling it with other data sources. Yet, buried in the details of the 867 transaction stream are precise images of the activities of downstream channel customers, which can reveal discrepancies that can compromise manufacturer revenue, product availability and integrity, and even patient safety. For these reasons, mastering the 867 can yield significant rewards.

This paper demystifies the often incomplete and always massive EDI 867 document to assess its true economic value to the pharmaceutical manufacturer and, by extension, to wholesaler partners. As the distribution channel becomes more collaborative, capturing the essentials of the 867 provides another step towards a transparent and safe route to the patient.

Complete white paper can be found at: http://www.edgedynamics.com/